Translational Oncology: How to Better Transform Targets into Relevant Drugs for Patients

Moderators: Jeffrey M. Bockman, PhD, VP, Defined Health Mike Rice, MS, MBA, Senior Consultant, Defined Health Panelists: Joseph Beechem, PhD, SVP, Research and Development, NanoString Technologies Pamela Carroll, PhD, VP, Oncology, Innovation Center in Boston, Janssen Research & Development Rajesh Chopra, MD, PhD, Corporate VP, Translational and Early Drug Development, Celgene Corporation Victoria Richon, PhD, […]

Challenging Established Paradigms in Cancer

Moderator: Sol J. Barer, PhD, SJBarer Consulting LLC Panelists: Rajesh Chopra, MD, PhD, Corporate VP, Translational and Early Drug Development, Celgene Corporation Giulio Draetta, MD, PhD, Director, Institute for Applied Cancer Science, Professor, Genomic Medicine, MD Anderson Cancer Center Tak Mak, PhD, University Professor, Ontario Cancer Institute, University of Toronto Neal Rosen, MD, PhD, Director, Center […]

Intrinsic and Acquired Resistance in Cancer: Getting Smarter About Combinations and Sequencing

Moderator: Neal Rosen, MD, PhD, Director, Center for Mechanism-Based Therapeutics, Memorial Sloan-Kettering Cancer Center Panelists: Jeffrey A. Engelman, MD, PhD, Director of Thoracic Oncology and Director of Molecular Therapeutics, Massachusetts General Hospital Cancer Center Greg Plowman, MD, PhD, VP, Oncology Research Eli Lilly and Company David Solit, MD, Director, Developmental Therapeutics, Memorial Sloan-Kettering Cancer Center